Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months

Alberto F. Sobrero(Ospedale Policlinico San Martino), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Marc Ychou(Université de Montpellier), Josep Tabernero(Deaconess Hospital), Antoine Adenis(Inserm), Salvatore Siena(University of Milan), Axel Grothey(Campbell Clinic), Takayuki Yoshino(University of Tsukuba), Laurent Mineur(Institut Sainte Catherine), Carlo Barone(Institut d'Etudes Politiques de Paris), Olivier Bouché(CHU Dijon Bourgogne), Richard M. Goldberg(Ontario Institute for Cancer Research), Heinz-Josef Lenz(University of Southern California), Liang Xu(Shandong Provincial Hospital), Yves Humblet(Deventer Ziekenhuis), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi)
Annals of Oncology
October 1, 2015
10.1093/annonc/mdv340.13
Cited by 0

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k